Page last updated: 2024-12-11
flavasperone
Description
flavasperone: inhibits ACAT2; isolated from Aspergillus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
flavasperone : A naphtho-gamma-pyrone that is 4H-naphtho[1,2-b]pyran-4-one carrying a methyl substituent at position2, a hydroxy substituent at position 5 and two methoxy substotuents at positions 8 and 10. Originally isolated from Aspergillus niger. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (19)
| Synonym |
|---|
| unii-qus3f7kq3e |
| qus3f7kq3e , |
| 4h-naphtho(1,2-b)pyran-4-one, 5-hydroxy-8,10-dimethoxy-2-methyl- |
| asperxanthon |
| tmc 256c2 |
| antibiotic tmc 256c2 |
| CHEBI:133814 |
| 5-hydroxy-8,10-dimethoxy-2-methyl-4h-naphtho[1,2-b]pyran-4-one |
| asperxanthone |
| flavasperone |
| 3566-99-2 |
| 5-hydroxy-8,10-dimethoxy-2-methyl-4h-benzo[h]chromen-4-one |
| flavasperon |
| SCHEMBL16226658 |
| DTXSID40189166 |
| 5-hydroxy-8,10-dimethoxy-2-methyl-4h-naphtho[1,2-b]pyran-4-one, 9ci |
| tmd256c2 |
| 5-hydroxy-8,10-dimethoxy-2-methyl-4h-naphtho(1,2-b)pyran-4-one |
| CHEMBL4645135 |
Roles (4)
| Role | Description |
|---|
| acyl-CoA:cholesterol acyltransferase 2 inhibitor | A sterol O-acyltransferase inhibitor that specifically inhibits acyl-CoA:cholesterol acyltransferase 2. |
| Aspergillus metabolite | Any fungal metabolite produced during a metabolic reaction in the mould, Aspergillus. |
| marine metabolite | Any metabolite produced during a metabolic reaction in marine macro- and microorganisms. |
| antiviral agent | A substance that destroys or inhibits replication of viruses. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| naphtho-gamma-pyrone | Any naphthopyran whose skeleton consists of a naphathalene ring system ortho-fused to a gamma-pyrone. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1651643 | Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 3 hrs followed by LPS-stimulation and measured after 24 hrs by Griess reagent based assay | 2020 | Journal of natural products, 04-24, Volume: 83, Issue:4
| Anti-inflammatory Metabolites from |
| AID1777026 | Anticancer activity against cisplatin-resistant human A549 cells assessed as reduction in cell viability measured after 48 hrs in presence of cisplatin by MTT assay | | | |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.68
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.68 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.63 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |